Hepatitis-C Patients Have Reduced Growth Hormone (GH) Secretion Which Improves During Long-Term Therapy With Pegylated Interferon-α

Plöckinger, Ursula; Krüger, Denny; Bergk, A.; Weich, V.; Wiedenmann, Bertram; Berg, Thomas

doi:10.1111/j.1572-0241.2007.01445.x

Cited by 19 publications

(18 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our studies, examination of serum IGF-1 concentration confirmed previous reports which observed lower concentrations in CH-C or in HCV-related liver cirrhosis, as compared to the control (25,26,29,31,32,48). Patients with chronic HCV infection manifested GH insufficiency and persistent GH resistance of hepatocytes, which may also promote a decrease in liver production of IGF-1 (48).…”

Section: Discussionsupporting

confidence: 77%

See 1 more Smart Citation

The insulin-like growth factor-1 and expression of its binding protein-3 in chronic hepatitis C and hepatocellular carcinoma

Adamek¹,

Kasprzak²,

Mikos³

et al. 2013

Oncology Reports

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 77%

“…Patients with chronic HCV infection manifested GH insufficiency and persistent GH resistance of hepatocytes, which may also promote a decrease in liver production of IGF-1 (48). In patients with HCV-related cirrhosis, it was even demonstrated that the reduction in IGF-1 level preceded the diagnosis of HCC by 9.3±3.1 months (29).…”

Section: Discussionmentioning

confidence: 94%

The insulin-like growth factor-1 and expression of its binding protein-3 in chronic hepatitis C and hepatocellular carcinoma

Adamek¹,

Kasprzak²,

Mikos³

et al. 2013

Oncology Reports

View full text Add to dashboard Cite

“…This finding was supported by authors who found that transaminases have not correlated with growth hormone concentrations before or during therapy [33]. However, our observation found a significant positive correlation between growth hormone and pre-treatment ALT concentration in responder subjects and infected patients.…”

Section: Discussionsupporting

confidence: 78%

“…They added that basal and stimulated growth hormone concentrations increased significantly during antiviral therapy [33][34][35]. Some of them added that there was high significant increase of GH in responders compared to nonresponders after treatment [35].…”

Section: Introductionmentioning

confidence: 99%

Correlation and Multiple Regression Analyses of Pituitary Growth Hormone and Hepatic Activities in Hepatitis C Infection and Interferon Response

et al. 2013

View full text Add to dashboard Cite

The prevalence of hepatitis C virus (HCV) infection varies across the world, with the highest percent of infections reported in Middle East, increasingly in Egypt. The current study aimed at examining the bio-statistical correlation and multiple regression analyses of pituitary growth hormone (GH) and liver activities among HCV genotype-4 patients treated with PEG-IFN-a plus RBV therapy. Herein, the current study was conducted on 100 HCV genotype-4 infected patients and 50 healthy controls. Patients received PEG-IFN-a/RBV for 24 weeks. Host RNA was isolated from patients' sera for HCV genotyping and viral load determination. Moreover, the enzymatic activities of the liver, AFP, GH, PT, and CBC were performed in all volunteers. The present study resulted that the activities of the hepatic enzymes among HCV genotype-4 patients correlated together significantly. While, human GH showed a significant positive regression with pre-treatment ALT concentration in responders. Furthermore, multiple regression analysis for GH showed a significant positive correlation with pre-treatment ALT in HCV genotype-4 infected patients. We concluded that there were a putative significant relation between GH and pre-treatment ALT activity in HCV infection and response to IFN-based therapy.

show abstract

“…Previous studies suggested that GH1 in HCV German [13] and Egyptian [14] patients was significantly decreased and increased significantly after antiviral therapy with interferon. Growth hormone (GH1) resistance is present in chronic liver disease (CLD) from the early stages.…”

Section: Introductionmentioning

confidence: 99%

Does HCV Patients Who Have BCL2 43Ala Genotype and Normal GH1 Levels Can Achieve Response to IFN Based Therapy?

et al. 2012

View full text Add to dashboard Cite

The main objective of the current study is to examine the role of the statistical relation between BCL2 gene (Ala43Thr) single nucleotide polymorphism and growth hormone (GH1) levels in Egyptian HCV genotype-4 patients before and after treatment with pegylated interferon plus ribavirin. Eighty patients with HCV genotype-4 and 40 healthy volunteers as controls were enrolled in the prospective study. Gene polymorphism of BCL2 (Ala43Thr) using PCR-RFLP technique and GH1 concentrations using ELISA procedure were measured for all patients and controls. The present study resulted that Responder HCV genotype-4 Patients, with BCL2 43Ala genotype, have high significant increase in pre-treatment GH1 levels ([1 ng/ml); which represent normal levels, as compared to non-responders pre-treatment GH1 levels (\1 ng/ml); which represent low concentrations. We concluded that HCV genotype-4 patients who have normal GH1 concentrations and BCL-2 43Ala genotype can successfully achieve response to interferon based therapy.

show abstract

Hepatitis-C Patients Have Reduced Growth Hormone (GH) Secretion Which Improves During Long-Term Therapy With Pegylated Interferon-α

Cited by 19 publications

References 57 publications

The insulin-like growth factor-1 and expression of its binding protein-3 in chronic hepatitis C and hepatocellular carcinoma

The insulin-like growth factor-1 and expression of its binding protein-3 in chronic hepatitis C and hepatocellular carcinoma

Correlation and Multiple Regression Analyses of Pituitary Growth Hormone and Hepatic Activities in Hepatitis C Infection and Interferon Response

Does HCV Patients Who Have BCL2 43Ala Genotype and Normal GH1 Levels Can Achieve Response to IFN Based Therapy?

Contact Info

Product

Resources

About